Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 1
2004 1
2005 3
2006 2
2007 12
2008 10
2009 7
2010 16
2011 11
2012 7
2013 11
2014 13
2015 5
2016 10
2017 8
2018 7
2019 13
2020 17
2021 12
2022 16
2023 10
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

170 results

Results by year

Filters applied: . Clear all
Page 1
Radionuclides.
Kapoor A, Hotte SJ. Kapoor A, et al. Among authors: hotte sj. Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S144-S145. doi: 10.5489/cuaj.4056. Can Urol Assoc J. 2016. PMID: 27895811 Free PMC article. Review. No abstract available.
In Reply.
Coomes EA, Al-Shamsi HO, Meyers BM, Alhazzani W, Alhuraiji A, Chemaly RF, Almuhanna M, Wolff RA, Ibrahim NK, Chua MLK, Hotte SJ, Elfiki T, Curigliano G, Eng C, Grothey A, Xie C. Coomes EA, et al. Among authors: hotte sj. Oncologist. 2020 Aug;25(8):e1252-e1253. doi: 10.1634/theoncologist.2020-0329. Epub 2020 May 27. Oncologist. 2020. PMID: 32378772 Free PMC article.
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA.
Matsubara N, de Bono J, Olmos D, Procopio G, Kawakami S, Ürün Y, van Alphen R, Flechon A, Carducci MA, Choi YD, Hotte SJ, Korbenfeld E, Kramer G, Agarwal N, Chi KN, Dearden S, Gresty C, Kang J, Poehlein C, Harrington EA, Hussain M. Matsubara N, et al. Among authors: hotte sj. Clin Cancer Res. 2023 Jan 4;29(1):92-99. doi: 10.1158/1078-0432.CCR-21-3577. Clin Cancer Res. 2023. PMID: 36318705 Free PMC article. Clinical Trial.
Localized prostate cancer.
Kapoor A, Hotte SJ. Kapoor A, et al. Among authors: hotte sj. Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S138-S139. doi: 10.5489/cuaj.4054. Can Urol Assoc J. 2016. PMID: 27895809 Free PMC article. Review. No abstract available.
Management algorithms for metastatic prostate cancer.
Malone S, Shayegan B, Basappa NS, Chi K, Conter HJ, Hamilton RJ, Hotte SJ, Saad F, So AI, Park-Wyllie L, Hew H, McLeod D, Gotto G. Malone S, et al. Among authors: hotte sj. Can Urol Assoc J. 2020 Feb;14(2):50-60. doi: 10.5489/cuaj.5840. Can Urol Assoc J. 2020. PMID: 31039111 Free PMC article. Review.
Reversible Cabozantinib-Induced Cardiomyopathy.
Alhussein M, Hotte SJ, Leong DP. Alhussein M, et al. Among authors: hotte sj. Can J Cardiol. 2019 Apr;35(4):544.e1-544.e2. doi: 10.1016/j.cjca.2018.12.025. Epub 2018 Dec 29. Can J Cardiol. 2019. PMID: 30935646
Androgen receptor axis-targeted agents.
Kapoor A, Hotte SJ. Kapoor A, et al. Among authors: hotte sj. Can Urol Assoc J. 2016 Aug;10(7-8Suppl3):S146-S148. doi: 10.5489/cuaj.4057. Can Urol Assoc J. 2016. PMID: 27895812 Free PMC article. Review. No abstract available.
Canadian consensus statement on the management of radioactive iodine-resistant differentiated thyroid cancer.
Boucher A, Ezzat S, Hotte S, Rachinsky I, Rajaraman M, Ruether D, Wiseman SM, Brierley J, Ho C, Krzyzanowska M, Lamond N, Massicotte MH, Joseph S, Herscovitch K, Sikora L, Winquist E. Boucher A, et al. Among authors: hotte s. Oral Oncol. 2021 Oct;121:105477. doi: 10.1016/j.oraloncology.2021.105477. Epub 2021 Aug 10. Oral Oncol. 2021. PMID: 34388408 Free article. Review.
Treatment of mCRPC in the AR-axis-targeted therapy-resistant state.
Chi K, Hotte SJ, Joshua AM, North S, Wyatt AW, Collins LL, Saad F. Chi K, et al. Among authors: hotte sj. Ann Oncol. 2015 Oct;26(10):2044-56. doi: 10.1093/annonc/mdv267. Epub 2015 Jun 22. Ann Oncol. 2015. PMID: 26101426 Free article. Review.
FRACTION-RCC: nivolumab plus ipilimumab for advanced renal cell carcinoma after progression on immuno-oncology therapy.
Choueiri TK, Kluger H, George S, Tykodi SS, Kuzel TM, Perets R, Nair S, Procopio G, Carducci MA, Castonguay V, Folefac E, Lee CH, Hotte SJ, Miller WH Jr, Saggi SS, Lee CW, Desilva H, Bhagavatheeswaran P, Motzer RJ, Escudier B. Choueiri TK, et al. Among authors: hotte sj. J Immunother Cancer. 2022 Nov;10(11):e005780. doi: 10.1136/jitc-2022-005780. J Immunother Cancer. 2022. PMID: 36328377 Free PMC article. Clinical Trial.
170 results